Skip to main content

OncoDNA, Institut Curie Partner on Liquid Biopsy Research in Head and Neck Cancer

NEW YORK – OncoDNA and Institut Curie in France on Thursday said they have partnered to evaluate liquid biopsy-based treatment monitoring for head and neck cancer patients.

The partnership will integrate OncoDNA's OncoFollow, a blood-based next-generation sequencing test, into the Institut Curie's ongoing prospective biobanking SCANDARE study. The SCANDARE investigators will longitudinally administer OncoFollow tests to patients at different stages of their treatment, including when they have surgery, and receive chemotherapy or radiation therapy, if applicable. They will use the test to monitor patients for disease progression and guide treatment selection should they develop new mutations.

"Liquid biopsies could be valuable alternatives to solid biopsies, which are sometimes delicate in this particular disease," Christophe Le Tourneau, senior medical oncologist at Institut Curie and one of the principal investigators in SCANDARE, said in a statement.

The OncoFollow tests will assess patients' circulating tumor DNA for mutations in 40 established genes associated with oncogenesis or treatment response, as well as 14 additional variants customized according to each patient's tumor. OncoDNA and Institut Curie will analyze nearly 300 plasma samples within SCANDARE.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.